Fig. 7: CLL cells after ibrutinib treatment remain sensitive to TG02. | Blood Cancer Journal

Fig. 7: CLL cells after ibrutinib treatment remain sensitive to TG02.

From: The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action

Fig. 7

A (top) The lymphocyte count of the CLL patient before (Pre) and 4 weeks after (W4) ibrutinib treatment. A (bottom) Dose response to TG02 in CLL cells pre- and post- ibrutinib treatment. CLL cells isolated from CLL patients pre- (Pre, ○) and 4 weeks (W4, •) post ibrutinib were incubated for 24 h with TG02, and cell death was measured by flow cytometry. B The IC50 values of TG02 pre- (○) and 4 weeks (•) post ibrutinib were compared by Wilcoxon paired test (n = 12). C Dose response to TG02 in cells from a CLL patient collected prior to ibrutinib treatment (Pre) and at the time of refractory (Refractory).

Back to article page